- Icelandirect has acquired SOMA LABS, a New Jersey-based supplement manufacturer, with the transaction closing in February 2026.
- The deal expands Icelandirect’s manufacturing capabilities to include powders, capsules, tablets, and chewables for human and pet supplement markets.
Icelandirect, a portfolio company of New Heritage Capital, has acquired SOMA LABS, a supplement manufacturer based in New Jersey, in a transaction that closed in February 2026. The acquisition expands Icelandirect’s contract manufacturing capabilities across both human nutrition and pet supplement markets.
The company stated that the acquisition is focused on enhancing its ability to manufacture a broader range of dosage forms. Previously known for lipid and softgel supplement sourcing, formulation, manufacturing, and packaging, Icelandirect will now add powders, tablets, capsules, and chewable formats to its offering.
As part of the integration, SOMA LABS will operate as a division of Icelandirect, with its New Jersey facility remaining operational. The companies are aligning leadership, technical teams, and quality systems to support continuity of service while expanding manufacturing capabilities for existing and new customers.
The expanded capabilities include custom powder blending and filling, hard-shell capsule production, compressed tablet manufacturing, and chewable formats for both human and pet supplements. These additions are intended to support a wider range of product formats and manufacturing requirements.
“The acquisition of SOMA LABS will allow us to add powder, tablet, capsule, and chewable capabilities, thus delivering a turnkey product offering to our clients. These new offerings allow us to take a brand from ingredient and formula all the way through to finished, shelf-ready product — in more formats, at greater scale, and with the quality standards our customers have come to expect from Icelandirect.”
Brandon Miller, CEO of Icelandirect
